SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Lind Lars) srt2:(2015-2019);srt2:(2019)"

Sökning: WFRF:(Lind Lars) > (2015-2019) > (2019)

  • Resultat 1-10 av 83
  • [1]234567...9Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  •  
4.
  • Justice, Anne E., et al. (författare)
  • Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution
  • 2019
  • Ingår i: Nature Genetics. - Nature Publishing Group. - 1061-4036 .- 1546-1718. ; 51:3, s. 452-469
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Body-fat distribution is a risk factor for adverse cardiovascular health consequences. We analyzed the association of body-fat distribution, assessed by waist-to-hip ratio adjusted for body mass index, with 228,985 predicted coding and splice site variants available on exome arrays in up to 344,369 individuals from five major ancestries (discovery) and 132,177 European-ancestry individuals (validation). We identified 15 common (minor allele frequency, MAF &gt;= 5%) and nine low-frequency or rare (MAF &lt; 5%) coding novel variants. Pathway/gene set enrichment analyses identified lipid particle, adiponectin, abnormal white adipose tissue physiology and bone development and morphology as important contributors to fat distribution, while cross-trait associations highlight cardiometabolic traits. In functional follow-up analyses, specifically in Drosophila RNAi-knockdowns, we observed a significant increase in the total body triglyceride levels for two genes (DNAH10 and PLXND1). We implicate novel genes in fat distribution, stressing the importance of interrogating low-frequency and protein-coding variants.</p>
  •  
5.
  • Karasik, David, et al. (författare)
  • Disentangling the genetics of lean mass
  • 2019
  • Ingår i: American Journal of Clinical Nutrition. - Oxford University Press. - 0002-9165 .- 1938-3207. ; 109:2, s. 276-287
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Background: Lean body mass (LM) plays an important role in mobility and metabolic function. We previously identified five loci associated with LM adjusted for fat mass in kilograms. Such an adjustment may reduce the power to identify genetic signals having an association with both lean mass and fat mass. Objectives: To determine the impact of different fat mass adjustments on genetic architecture of LM and identify additional LM loci. Methods: We performed genome-wide association analyses for whole-body LM (20 cohorts of European ancestry with n = 38,292) measured using dual-energy X-ray absorptiometry) or bioelectrical impedance analysis, adjusted for sex, age, age(2), and height with or without fat mass adjustments (Model 1 no fat adjustment; Model 2 adjustment for fat mass as a percentage of body mass; Model 3 adjustment for fat mass in kilograms). Results: Seven single-nucleotide polymorphisms (SNPs) in separate loci, including one novel LM locus (TNRC6B), were successfully replicated in an additional 47,227 individuals from 29 cohorts. Based on the strengths of the associations in Model 1 vs Model 3, we divided the LM loci into those with an effect on both lean mass and fat mass in the same direction and refer to those as "sumo wrestler" loci (FTO and MC4R). In contrast, loci with an impact specifically on LMwere termed "body builder" loci (VCAN and ADAMTSL3). Using existing available genome-wide association study databases, LM increasing alleles of SNPs in sumo wrestler loci were associated with an adverse metabolic profile, whereas LM increasing alleles of SNPs in "body builder" loci were associated with metabolic protection. Conclusions: In conclusion, we identified one novel LM locus (TNRC6B). Our results suggest that a genetically determined increase in lean mass might exert either harmful or protective effects on metabolic traits, depending on its relation to fat mass.</p>
  •  
6.
  • Lind, Lars, et al. (författare)
  • On the association between body fat and left ventricular mass
  • 2019
  • Ingår i: Journal of Hypertension. - 0263-6352 .- 1473-5598. ; 37:8, s. 1699-1704
  • Tidskriftsartikel (refereegranskat)abstract
    • <p><strong>OBJECTIVES:</strong> As intervention studies have shown a reduction in body weight to be paralleled with a reduction in left ventricular mass (LVM), we quantified a hypothesized causal relationship between fat mass and LVM, and how much of these effects that was mediated by blood pressure (BP), diabetes and adipokines. Also visceral and subcutaneous adipose tissue (VAT and SAT) were explored in the same fashion.</p><p><strong>METHODS:</strong> In the Prospective Study of the Vasculature in Uppsala Seniors study (n = 1016, 50% women, all aged 70 years), LVM was measured by echocardiography (indexed for lean mass, LVMI), fat and lean mass by dual-energy X-ray. VAT and SAT were measured by abdominal MRI (in n = 275).</p><p><strong>RESULTS:</strong> In a structural equation model adjusting for sex, the total effect of fat mass on LVMI was large (standardized coefficient 0.280, P = 3.2 × 10, 95% confidence interval 0.210-0.349). Out of the total effect of fat mass on LVMI, 29.0% was mediated by BP and glucose (P = 2.4 × 10). The BP pathway was most important, mediating 24.4% of the total effect of fat mass on LVMI (P = 4.6 × 10), while the glucose pathway accounted for 4.6% (P = 0.033). The association of VAT with LVMI (0.202, P = 2.4 × 10) was slightly weaker than that of SAT with LVMI (0.283, P = 1.0 × 10). Of several measured adipokines, leptin was a significant mediator of the effect of fat mass on LVMI (P = 3.0 × 10).</p><p><strong>CONCLUSION:</strong> One-third of the hypothesized association between body fat and LVMI was mediated by BP and glucose in this population-based cohort. Leptin was also an important mediator. Visceral adipose tissue was not more closely related to LVMI than subcutaneous abdominal fat.</p>
  •  
7.
  • Lind, Lars, et al. (författare)
  • On the association between body fat and left ventricular mass
  • 2019
  • Ingår i: Journal of Hypertension. - 0263-6352 .- 1473-5598. ; 37:8, s. 1699-1704
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Objectives: As intervention studies have shown a reduction in body weight to be paralleled with a reduction in left ventricular mass (LVM), we quantified a hypothesized causal relationship between fat mass and LVM, and how much of these effects that was mediated by blood pressure (BP), diabetes and adipokines. Also visceral and subcutaneous adipose tissue (VAT and SAT) were explored in the same fashion.</p><p>Methods: In the Prospective Study of the Vasculature in Uppsala Seniors study (<em>n</em> = 1016, 50% women, all aged 70 years), LVM was measured by echocardiography (indexed for lean mass, LVMI), fat and lean mass by dual-energy X-ray. VAT and SAT were measured by abdominal MRI (in <em>n</em> = 275).</p><p>Results: In a structural equation model adjusting for sex, the total effect of fat mass on LVMI was large (standardized coefficient 0.280, <em>P</em> = 3.2 × 10−15, 95% confidence interval 0.210–0.349). Out of the total effect of fat mass on LVMI, 29.0% was mediated by BP and glucose (<em>P</em> = 2.4 × 10−12). The BP pathway was most important, mediating 24.4% of the total effect of fat mass on LVMI (<em>P</em> = 4.6 × 10−7), while the glucose pathway accounted for 4.6% (<em>P</em> = 0.033). The association of VAT with LVMI (0.202, <em>P</em> = 2.4 × 10−4) was slightly weaker than that of SAT with LVMI (0.283, <em>P</em> = 1.0 × 10−6). Of several measured adipokines, leptin was a significant mediator of the effect of fat mass on LVMI (<em>P</em> = 3.0 × 10−3).</p><p>Conclusion: One-third of the hypothesized association between body fat and LVMI was mediated by BP and glucose in this population-based cohort. Leptin was also an important mediator. Visceral adipose tissue was not more closely related to LVMI than subcutaneous abdominal fat.</p>
  •  
8.
  • Lind, Susanne, et al. (författare)
  • The integrated palliative care outcome scale for patients with palliative care needs : Factors related to and experiences of the use in acute care settings
  • 2019
  • Ingår i: Palliative and Supportive Care. - Cambridge University Press. - 1478-9515. ; 17:5, s. 561-568
  • Tidskriftsartikel (refereegranskat)abstract
    • ObjectiveImplementation of patient-reported outcome measures for patients with palliative care needs is characterized by both enablers and barriers. The ways in which healthcare professionals experience the use of assessment tools is important. Our aims were to explore factors contributing to or hindering patients with palliative care needs in assessing their symptoms with the Integrated Palliative Care Outcome Scale (IPOS) and to explore healthcare professionals' experiences of the use of IPOS in acute care settings.MethodData were collected as a part of the evaluation of the feasibility of an implementation strategy for introducing IPOS. Data from three participating acute care units were included. We used descriptive and analytical statistics; a qualitative content analysis was also performed.ResultA total of 309 patients were eligible to be offered assessment of symptoms with IPOS. Of these 69 (22%) had completed IPOS. A significant positive association was found between healthcare professionals' participation in training sessions and completed IPOS. The experiences of IPOS were split into two categories: "IPOS acting as a facilitator" and "barriers to the use of IPOS." The use of IPOS was described as contributing to person-centered care of patients with palliative care needs and inspiration to improved routines. Healthcare professionals' feelings of uncertainty about how to approach severely ill patients and their family members appear to have hindered their use of IPOS.Significance of resultsWe found an association between healthcare professionals' participation in training sessions and patients who completed IPOS, indicating the need for a high degree of attendance at the training to achieve successful implementation. The healthcare professionals expressed feelings of insecurity concerning the use of IPOS indicating a need for further education and clinical support in its use of IPOS. Nevertheless, use of IPOS was considered to contribute to improved care of patients with palliative care needs.
  •  
9.
  • Salihovic, Samira, et al. (författare)
  • Identification of metabolic profiles associated with human exposure to perfluoroalkyl substances.
  • 2019
  • Ingår i: Journal of Exposure Science and Environmental Epidemiology. - 1559-0631 .- 1559-064X. ; 29:2, s. 196-205
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Recent epidemiological studies suggest that human exposure to perfluoroalkyl substances (PFASs) may be associated with type 2 diabetes and other metabolic phenotypes. To gain further insights regarding PFASs exposure in humans, we here aimed to characterize the associations between different PFASs and the metabolome. In this cross-sectional study, we investigated 965 individuals from Sweden (all aged 70 years, 50% women) sampled in 2001-2004. PFASs were analyzed in plasma using isotope-dilution ultra-pressure liquid chromatography coupled to tandem mass spectrometry (UPLC-MS/MS). Non-target metabolomics profiling was performed in plasma using UPLC coupled to time-of-flight mass spectrometry (UPLC-QTOFMS) operated in positive electrospray mode. Multivariate linear regression analysis was used to investigate associations between circulating levels of PFASs and metabolites. In total, 15 metabolites, predominantly from lipid pathways, were associated with levels of PFASs following adjustment for sex, smoking, exercise habits, education, energy, and alcohol intake, after correction for multiple testing. Perfluorononanoic acid (PFNA) and perfluoroundecanoic acid (PFUnDA) were strongly associated with multiple glycerophosphocholines and fatty acids including docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA). We also found that the different PFASs evaluated were associated with distinctive metabolic profiles, suggesting potentially different biochemical pathways in humans.</p>
  •  
10.
  • Schmidt, Amand F., et al. (författare)
  • Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
  • 2019
  • Ingår i: BMC Cardiovascular Disorders. - BMC. - 1471-2261 .- 1471-2261. ; 19:1
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Background: We characterised the phenotypic consequence of genetic variation at the PCSK9 locus and compared findings with recent trials of pharmacological inhibitors of PCSK9. Methods: Published and individual participant level data (300,000+ participants) were combined to construct a weighted PCSK9 gene-centric score (GS). Seventeen randomized placebo controlled PCSK9 inhibitor trials were included, providing data on 79,578 participants. Results were scaled to a one mmol/L lower LDL-C concentration. Results: The PCSK9 GS (comprising 4 SNPs) associations with plasma lipid and apolipoprotein levels were consistent in direction with treatment effects. The GS odds ratio (OR) for myocardial infarction (MI) was 0.53 (95% CI 0.42; 0.68), compared to a PCSK9 inhibitor effect of 0.90 (95% CI 0.86; 0.93). For ischemic stroke ORs were 0.84 (95% CI 0.57; 1.22) for the GS, compared to 0.85 (95% CI 0.78; 0.93) in the drug trials. ORs with type 2 diabetes mellitus (T2DM) were 1.29 (95% CI 1.11; 1.50) for the GS, as compared to 1.00 (95% CI 0.96; 1.04) for incident T2DM in PCSK9 inhibitor trials. No genetic associations were observed for cancer, heart failure, atrial fibrillation, chronic obstructive pulmonary disease, or Alzheimer's disease - outcomes for which large-scale trial data were unavailable. Conclusions: Genetic variation at the PCSK9 locus recapitulates the effects of therapeutic inhibition of PCSK9 on major blood lipid fractions and MI. While indicating an increased risk of T2DM, no other possible safety concerns were shown; although precision was moderate.</p>
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 83
  • [1]234567...9Nästa
Åtkomst
fritt online (33)
Typ av publikation
tidskriftsartikel (73)
konferensbidrag (5)
bokkapitel (3)
doktorsavhandling (2)
Typ av innehåll
refereegranskat (75)
övrigt vetenskapligt (15)
Författare/redaktör
Lind, Lars, (54)
Giedraitis, Vilmanta ... (16)
Sundström, Johan, (13)
Ingelsson, Erik (12)
Söderberg, Stefan, (12)
Rosengren, Annika (11)
visa fler...
Pedersen, Nancy L (11)
Janson, Christer, (10)
Svennblad, Bodil, (10)
Olsson, Håkan, (9)
Rosenblad, Andreas, (8)
Engström, Gunnar, (7)
Wanhainen, Anders, (7)
Smith, Albert V. (7)
Gudnason, Vilmundur (7)
Uitterlinden, Andre ... (7)
Morris, Andrew P. (7)
Larsson, Anders, (6)
Nilsson, Peter M, (6)
Weiderpass, Elisabet ... (6)
Wolk, Alicja (6)
Teumer, Alexander (6)
Psaty, Bruce M. (6)
Ärnlöv, Johan, 1970- ... (6)
Koupil, Ilona, (6)
Johansson, Ingegerd, (6)
Laakso, Markku, (6)
Magnusson, Patrik K ... (6)
Luan, Jian'an (6)
Feitosa, Mary F. (6)
Wernersson, Lars-Eri ... (5)
Ingelsson, Martin, (5)
Rotter, Jerome I. (5)
Ikram, M. Arfan (5)
Lind, L (5)
Björkelund, Cecilia (5)
Lindberg, Eva, (5)
Strauch, Konstantin (5)
Wennberg, Patrik, (5)
Rivadeneira, Fernand ... (5)
Heid, Iris M. (5)
Hayward, Caroline (5)
Perola, Markus (5)
Kovacs, Peter (5)
Stumvoll, Michael (5)
Boerwinkle, Eric (5)
Harris, Tamara B. (5)
Rudan, Igor (5)
Thorsteinsdottir, Un ... (5)
Lindgren, Cecilia M. (5)
visa färre...
Lärosäte
Uppsala universitet (29)
Lunds universitet (17)
Umeå universitet (9)
Karolinska Institutet (8)
Högskolan Dalarna (7)
Kungliga Tekniska Högskolan (6)
visa fler...
Linköpings universitet (4)
Göteborgs universitet (3)
Högskolan Kristianstad (2)
Örebro universitet (2)
Stockholms universitet (1)
Högskolan i Jönköping (1)
Mittuniversitetet (1)
Högskolan i Skövde (1)
Ersta Sköndal Bräcke högskola (1)
visa färre...
Språk
Engelska (83)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (67)
Naturvetenskap (8)
Teknik (6)
Samhällsvetenskap (4)
Humaniora (1)
År
 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy